Julie Gottlieb Fisher

Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Ajjai Alva, Pam K. Mangat, Elizabeth Garrett‐Mayer et al. · Journal of Clinical Oncology · 2021 · 175 citations

Expression of inhibitory receptor ILT3 on neoplastic B cells is associated with lymphoid tissue involvement in chronic lymphocytic leukemia

Adriana I. Colovai, Lawrence Tsao, Su Wang et al. · Cytometry Part B Clinical Cytometry · 2007 · 59 citations · Full text

LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases

Amanda E.D. Van Swearingen, Marni B. Siegel, Allison M. Deal et al. · Breast Cancer Research and Treatment · 2018 · 47 citations · Full text

Lccc 1025, Breast Oncology, Medicine +8

Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Julie Gottlieb Fisher, David L. Tait, Elizabeth Garrett‐Mayer et al. · Targeted Oncology · 2020 · 44 citations

Breast Oncology, Medicine, Pathology +8

Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Ajjai Alva, Pam K. Mangat, Elizabeth Garrett‐Mayer et al. · Journal of Clinical Oncology · 2019 · 32 citations

Breast Oncology, Immunology, Pathology +21